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Cholesterol oxides are atherogenic and can affect the activity of diverse important enzymes for the 
lipidic metabolism. The effect of 7b-hydroxycholesterol, 7-ketocholesterol, 25-hydroxycholesterol, 
cholestan-3b,5a,6b-triol,5,6b-epoxycholesterol, 5,6a-epoxycholesterol and 7a-hydroxycholesterol on 
esterification of cholesterol by lecithin:cholesterol acyl transferase (LCAT, EC 2.3.1.43) and the transfer 
of esters of cholesterol oxides from high density lipoprotein (HDL) to low density lipoproteins (LDL) 
and very low density lipoproteins (VLDL) by cholesteryl ester transfer protein (CETP) was investigated. 
HDL enriched with increasing concentrations of cholesterol oxides was incubated with fresh plasma 
as source of LCAT. Cholesterol and cholesterol oxides esterification was followed by measuring the 
consumption of respective free sterol and oxysterols. Measurements of cholesterol and cholesterol 
oxides were done by gas-chromatography. 14C-cholesterol oxides were incorporated into HDL
2 
and 
HDL
3
 subfractions and then incubated with fresh plasma containing LCAT and CETP. The transfer of 
cholesterol oxide esters was followed by measuring the 14C-cholesterol oxide-derived esters transferred 
to LDL and VLDL. All the cholesterol oxides studied were esterified by LCAT after incorporation into 
HDL particles, competing with cholesterol by LCAT. Cholesterol esterification by LCAT was inversely 
related to the cholesterol oxide concentration. The esterification of 14C-cholesterol oxides was higher 
in HDL
3
 and the transfer of the derived esters was greater from HDL
2
 to LDL and VLDL. The results 
suggest that cholesterol esterification by LCAT is inhibited in cholesterol oxide-enriched HDL particles. 
Moreover, the cholesterol oxides-derived esters are efficiently transferred to LDL and VLDL. Therefore, 
we suggest that cholesterol oxides may exert part of their atherogenic effect by inhibiting cholesterol 
esterification on the HDL surface and thereby disturbing reverse cholesterol transport.
Uniterms: Cholesterol/oxides. Cholesterol/acyl transferase. Lecithin. Protein/cholesteryl ester transfer. 
Lipoprotein/high density. Cholesterol/reverse transport.
Os óxidos de colesterol são aterogênicos e podem afetar a atividade de diversas enzimas importantes 
para o metabolismo lipídico. Este estudo investigou o efeito dos óxidos 7b-hidroxicolesterol, 
7-cetocolesterol, 25-hidroxicolesterol, colestan-3b,5a,6b-triol, 5,6b-epoxicolesterol, 5,6a-epoxicolesterol 
e 7a-hidroxicolesterol na esterificação do colesterol por ação da lecitina colesterol aciltransferase (LCAT, 
EC 2.3.1.43) e a posterior transferência dos óxidos esterificados da lipoproteína de alta densidade 
(HDL) para as lipoproteínas de baixa densidade (LDL) e muito baixa densidade (VLDL) mediada pela 
proteína de transporte de éster de colesterol (CETP). Para atingir os objetivos, HDL enriquecida com 
concentrações crescentes de óxidos de colesterol foi incubada com plasma fresco pobre em lipoproteínas, 
como fonte de LCAT; posteriormente a esterificação do colesterol e dos óxidos de colesterol foi medida 
pelo consumo do colesterol livre e dos óxidos livres presentes na HDL. As determinações de colesterol 
e dos óxidos de colesterol foram realizadas por cromatografia gasosa. 14C-óxidos de colesterol foram 
incorporados nas subfrações HDL
2 
e HDL
3
 e posteriormente incubados com plasma fresco, contendo 
LCAT e CETP. A transferência dos ésteres de óxidos de colesterol foi medida e quantificada pela 
presença desses ésteres na LDL e VLDL. Todos os óxidos de colesterol estudados foram esterificados 
pela LCAT após incorporação nas partículas de HDL e competiram com a esterificação do colesterol 
nativo. A esterificação do colesterol pela LCAT foi inversamente relacionada à concentração de óxidos de 
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colesterol. A esterificação dos óxidos de colesterol foi maior na HDL
3
 e a transferência desses ésteres foi 
maior a partir da HDL
2
 para a LDL e VLDL. Estes resultados indicam que a esterificação do colesterol 
pela LCAT é inibida nas partículas de HDL enriquecidas com óxidos de colesterol e que os ésteres de 
óxidos de colesterol são eficientemente transferidos para a LDL e VLDL. Portanto, sugere-se que os 
óxidos de colesterol exercem parte de seu efeito aterogênico pela inibição da esterificação do colesterol 
na superfície da HDL, causando um distúrbio no transporte reverso do colesterol, além de aumentar o 
potencial aterogênico da LDL e VLDL. 
Unitermos: Colesterol/óxidos. Colesterol/aciltransferase. Lecitina. Proteína/de transporte de éster de 
colesterol. Lipoproteína/de alta densidade. Colesterol/transporte reverso.
INTRODUCTION
High density lipoprotein (HDL) is the only anti-
atherosclerotic lipoprotein in plasma (Kawano et al., 2008) 
and plays an important role in the reverse cholesterol 
transport by removing cholesterol from peripheral cells to 
the liver and steroidogenic organs (Fielding and Fielding, 
1995; Von Eckardstein, 1996; Oram and Yokoyama, 1996). 
There is a widespread view that HDL protects against the 
development of atherosclerosis and counteracts the effects 
of LDL by removing cholesterol from cells of the arterial 
intima, thus preventing the formation of foam cells (Field-
ing, Fielding, 1995). In a specific pathway preb1-HDL 
(a HDL subfraction), interacts with cell membranes and 
takes up cholesterol via ATP-binding cassette (ABC) A1 
expressed on the cell surface (Kawano et al., 2008). The 
second major and critical step in reverse cholesterol trans-
port is the esterification of cholesterol on the HDL surface 
in a reaction catalyzed by lecithin:cholesterol acyl trans-
ferase (LCAT; EC 2.3.1.43). LCAT catalyzes the transfer 
of sn-2 acyl group from phosphatidylcholine to cholesterol 
(Glomset, 1968; Aron et al., 1978; Fielding, 1990), result-
ing in the movement of the formed cholesteryl esters to the 
center of the HDL, leaving the particle surface depleted 
of cholesterol. This creates a concentration gradient that 
promotes the transfer of cholesterol from cell membranes 
to HDL. An increased rate of LCAT-catalyzed cholesterol 
esterification will, therefore, enhance the rate of reverse 
cholesterol transport (Barter, Rye, 1996). This process is 
followed by the transfer of cholesteryl esters from HDL 
to apo B-containing lipoproteins in exchange for triglyc-
erides mediated by the cholesterol ester transfer protein 
(CETP) (Iglesias et al., 1996). This way, the cholesteryl 
esters formed in the HDL are mainly channeled to VLDL 
and LDL, and are finally removed primarily by the liver.
The interest on cholesterol oxides is mainly due 
to their various biological effects, such as, cytotoxicity, 
inhibition of HMG-CoA reductase activity, activation of 
ACAT, inhibition of LDL binding to cell receptors (Peng 
et al., 1991) as biomarker of oxidative stress (Ferderbar 
et al., 2007) and inhibition of cholesterol efflux from cells 
(Kilsdonk et al., 1995; Schroepfer, 2000). 
Oxysterols are the 27-carbon products of cholesterol 
oxidation by both enzymatic and non-enzymatic mecha-
nisms. Their roles on cholesterol homeostasis, as well as in 
diseases in which oxidative damage and lipid peroxidation 
are implicated (e.g. atherosclerosis), have been investi-
gated (Van Reyk et al., 2006). However, considering that 
the reverse cholesterol transport is a protective pathway of 
lipoprotein metabolism against cholesterol accumulation 
in the body, and considering that this mechanism would 
be interfered by cholesterol oxides, we investigated the 
effect of cholesterol oxides on cholesterol esterification 
by LCAT and the transfer of resulting cholesteryl esters 
formed in HDL to VLDL and LDL by CETP.
MATERIAL AND METHODS
Material
Cholesterol oxides (7b-hydroxyholesterol, 7-keto-
cholesterol, 25-hydroxycholesterol, cholestan-3b,5a,6b-
triol, 5,6b-epoxycholesterol, 5,6a-epoxycholesterol and 
7a-hydroxycholesterol) were purchased from Steraloids, 
Inc. (Wilton NH, USA); 14C-cholesterol was obtained from 
Amersham, Inc (Arlington Heights, IL); methanol (99 %), 
ethanol (99 %), chloroform (99 %), bis(trimethylsilyl)-
trifluoracetamide (BSTFA-98 %), N-hexane, acid acetic 
diethyl ether and N,N,dimethylphormamide were pur-
chased from Merck (Darmstadt, Germany); linoleic acid, 
lipoxidase from Glycine max (soybean), Na
2
 EDTA and 
NaCl were obtained from Sigma Aldrich (St. Louis, USA).
Lipoprotein isolation
Venous blood was obtained from overnight-fasted 
adult human volunteers. Blood was collected into 10 mL 
Vacutainer tubes containing EDTA (1 mg/mL blood). 
VLDL (d<1.0021) LDL (1.021<d>1.065), total HDL 
(1.065<d>1.210) and lipoprotein deficient serum (LPDS; 
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d>1.210) were separated by preparative sequential ul-
tracentrifugation with a Beckman 40T rotor (Redgrave, 
1975). HDL
2
 (1.065<d>1.125) and HDL
3
 (1.125<d>1.210) 
were separated from total HDL by saline gradient ultracen-
trifugation in a Hitachi 4 ST rotor (Redgrave, 1975). All 
the lipoproteins and the LPDS were exhaustively dialyzed 
at 4 °C against 0.15 M NaCl/1 mM-Na
2
EDTA, pH 7.4.
14C-cholesterol oxides formation
 To obtain 14C-cholesterol oxides, a solution con-
taining 1.89 mmol of 14C-cholesterol and 9.45 mmol of 
linoleic acid in ether was prepared. Borate buffer (0.2 
M, pH 9.0) was added to the solution and mixed to form 
micelles. After the solvent evaporation, lipoxidase (EC 
1.13.11.12 - 300.000 U) was added (Fruebis et al., 1992) 
and conjugated dienes kinetic formation was monitored 
at 234 nm (spectrophotometer UV-Vis U3000, Hitachi, 
Japan), to evaluate the lag phase of lipid peroxidation. 
When the lag phase was finished, more 300.000 U lipoxi-
dase were added to the system to ensure the total choles-
terol oxidation (Esterbauer et al., 1992). The solution was 
mixed overnight and the cholesterol oxides were isolated 
from cholesterol and other lipids as described previously 
(Sevanian, Mcleod, 1987). In this procedure 68 % of 
14C-cholesterol was oxidized. The pool of 14C-cholesterol 
oxides yielded from 14C-cholesterol oxidation was used 
in all experiments.
14C-cholesterol oxides and cholesterol oxides 
incorporation into HDL
Non-labeled cholesterol oxide standards or the pool 
of 14C-cholesterol oxides (0.15 mCi/mL) were added to 
glass vials and the solvent was evaporated under nitrogen. 
These cholesterol oxides were re-suspended in ethanol and 
a 2 mL solution of HDL (35 mg/dL cholesterol) was added. 
The mixture was incubated at 37 °C for 3 h in a shaking 
water bath. An aliquot of red blood cells suspension was 
added as described (Oda et al., 1990) to adsorb the cho-
lesterol and cholesterol oxides not incorporated into HDL.
Esterification of cholesterol oxides (standards and 
radiolabeled)
Cholesterol oxide-enriched HDL particles (along 
with radiolabeled cholesterol or cholesterol oxide stan-
dards) were incubated with lipoprotein deficient serum 
(LPDS, 60 mg/mL protein, source of LCAT) at 37 °C, for 
1h, in a shaking water bath. Immediately afterwards, the 
reaction was stopped by placing the tubes in ice. Aliquots 
were collected at the moment of LPDS addition and at the 
end of specified incubation times and analyzed by GC-FID 
(Hewlett Packard, HP-6890) to measure cholesterol oxides 
and by cintilography to evaluate 14C-cholesterol oxides. For 
the chromatographic analyzes samples were derivatized to 
trimethylsilyl (TMS) ethers and 4 mL aliquots were injected 
into the gas chromatograph equipped with flame ionization 
detector as described elsewhere (Sevanian et al., 1994).
Transfer of 14C-cholesteryl oxide esters from HDL 
to apoB-containing lipoproteins
14C-cholesterol-HDL subfractions (HDL
2
 and HDL
3
, 
previously incubated with LCAT) were incubated with 
LDL (140 mg/dl cholesterol) and VLDL (25 mg/dL choles-
terol) for 6 hours at 37 °C. The reactions were stopped on 
ice and lipoproteins reisolated by sequential ultracentrifu-
gation. Aliquots were extracted with chloroform:methanol 
(2:1) and the radioactivity analyzed in a liquid scintillation 
counter (Packard 1900 TR-liquid scintillation analyzer, 
Meriden, CT 06450). 5,5-Dithiobis-(2-nitrobenzoic acid 
(DTNB) was added in the transfer experiments to inhibit 
LCAT and p-chloromercuriphenylsulfonic acid (pCMPS) 
was added for CETP inhibition.
Free and esterified 14C-cholesterol oxide analysis
Free and esterified 14C-cholesterol oxides were sepa-
rated by thin layer chromatography using a solvent mixture 
consisting of n-hexane/diethyl ether/acetic acid/methanol 
(85:20:1:1; v/v/v/v) and the chromatographic plates were 
visualized using iodine vapor. The spots corresponding 
to free cholesterol and cholesteryl esters were scraped 
from the plates and re-suspended in scintillation solution 
(POPOP - 0,15 g; PPO - 5,0g; Triton - 500 mL; toluene 
q.s.p 1000 mL) to measure the radioactivity.
Statistical Analysis
Data are reported as means ± SEM. Statistical 
analysis was performed by the Tukey test as a post-test 
after ANOVA, with p < 0.05 considered to be significant 
(Sigma Stat software).
RESULTS AND DISCUSSION
Cholesterol oxides incorporation into HDL is shown 
at Table I. The percentage of incorporation of cholesterol 
oxides into HDL ranged from 11 to 60% with the highest 
incorporation found for the 7-ketocholesterol and the lowest 
for cholestan-3b,5a,6b-triol (triol), the lowest incorporation 
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of triol may be related to its higher hydrophilicity. All the 
cholesterol oxides incorporated into HDL were esterified by 
LCAT from human plasma (Figure 1). This is in accordance 
with data previously described for LCAT catalyzed esterifi-
cation of oxysterols in discoidal bilayer particles (Nishida 
et al., 1993). However, the esterification yield varied among 
the different cholesterol oxides with the lowest esterifica-
tion taking place with triol. This suggests that triol is not 
an efficient substrate for LCAT, possibly due to its higher 
hydrophilicity compared to the other cholesterol oxides, 
and/or steric hindrance from the 5,6-hydroxyl moieties, whi-
ch may reduce interaction with the hydrophobic catalytic 
site of LCAT (Peelman et al., 1998)
Figure 2 shows the esterification intensity of both cho-
lesterol and cholesterol oxides in the same HDL particle. It 
is noteworthy that the esterification of cholesterol is affected 
by the presence of cholesterol oxides in HDL. Most of the 
cholesterol oxides, except the triol and 7a-hydroxycholes-
terol, showed a trend for greater esterification compared to 
cholesterol. However, significant differences were observed 
only for 7-ketocholesterol and 5,6b-epoxycholesterol. The 
most pronounced inhibition of cholesterol esterification by 
LCAT was induced by 7-ketocholesterol.
The esterification of oxysterols catalyzed by LCAT 
was also affected when examined in HDL subfractions. 
14C-cholesterol oxide-enriched HDL subfractions showed 
different degrees of esterification efficiency. The 14C-
cholesterol oxides esterification was higher in the HDL
3
 
subfraction (2.6 ± 0.5 nCi, n=6) as compared to HDL
2
 (1.4 
± 0.3 nCi, n=6), as occurs for cholesterol esterification by 
LCAT. Accordingly, Fielding et al. (1989) proposed that 
the efflux of radiolabeled cholesterol from fibroblasts 
promoted by HDL, and its further esterification on this 
lipoprotein by LCAT, differed among HDL subfractions. 
The enhancement of LCAT activity was directly related 
with the increase of HDL
3
 and inversely correlated with 
HDL
2
 (Dobiasova et al., 1991, 1992).
The investigation of the influence of cholesterol oxi-
des concentration on cholesterol esterification showed that 
the inhibition of cholesterol esterification by LCAT was 
strongly dependent on cholesterol oxides concentration. 
As it can be seen at Table II, a concentration-dependent 
inhibition of cholesterol esterification was found, as the 
cholesterol oxide concentration increases in HDL particle.
Another important step for reverse cholesterol 
transport is the transfer of cholesteryl esters formed in 
HDL to the apo-B containing lipoproteins. Figures 3 and 
4 show the transfer of labeled cholesterol oxides present 
in HDL subfractions to LDL and VLDL, respectively. 14C-
cholesterol oxides were first esterified in HDL enriched 
particle in the presence or absence of DTNB (5,5-Dithio-
bis-(2-nitrobenzoic acid), a LCAT inhibitor. Later, these 
cholesterol oxides-enriched HDL particles were separately 
incubated with LDL and VLDL and LPDS, as source of 
TABLE I - Incorporation of cholesterol oxides into HDL
 incorporation into HDL (%)
cholesterol -
cholestan-3b,5a,6b-triol  11
25-hydroxycholesterol 53
cholesterylb-epoxide 54
7a-hydroxycholesterol 43
cholesteryla-epoxide 56
7b-hydroxycholesterol 40
7-ketocholesterol 60
FIGURE 1 - Esterification rate of cholesterol oxides incorporated 
into HDL, in relation to an HDL particle containing no 
cholesterol oxides. *Initial concentrations of cholesterol oxides 
(uM) incorporated into HDL.
FIGURE 2 - Esterification (%) of cholesterol and cholesterol 
oxides both in the same HDL particle. The relative esterification 
was calculated considering a sum of the esters formed from 
cholesterol and cholesterol oxides as 100% of esterification.
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CETP, in the presence or absence of pCMPS (p-chloro-
mercuriphenylsulfonic acid) which inhibits CETP. The 
results show that DTNB efficiently inhibited esterification 
by LCAT, although pCMPS inhibited only 50% of CETP 
activity. The transfer of labeled cholesterol oxide esters 
from HDL to LDL and VLDL was similar for both particles 
(approximately 50% of the labeled substrates being trans-
ferred in each case), which were incubated separately with 
HDL. The transfer of radiolabeled cholesterol oxide esters 
was higher in HDL
2
 subfraction (approximately 50%) as 
compared with HDL
3
 subfraction (approximately 13%). 
This may be due either to the HDL
2
 subfraction contai-
ning more cholesteryl esters or by a major interaction of 
this particle with CETP, as proposed by Jonas (1991) for 
cholesterol transfer. The major esterification of cholesterol 
and cholesterol oxides in HDL
3
 dynamically modifies this 
subfraction to the form HDL
2
, which is a better substrate 
for CETP that transforms the HDL
2
 again into HDL
3
.
TABLE II - Dependence of cholesterol and cholesterol oxide 
esterification rate on cholesterol oxide concentration
Cholesterol 
oxide
Concentration
(uM)
Cholesterol 
esterification 
rate
(umol/L/h)
Cholesterol oxide 
esterification rate
(umol/L/h)
25-hydroxy-
cholesterol
35
52
74.4
163
23.2
13.4
10.3
1.6
2.9
3.0
3.9
6.9
cholestan 3b, 
5a, 6b-triol
24.6
93
232
444
52.0
46.6
45.4
17.4
2.0
6.9
15.5
16.1
7a-hydroxy-
cholesterol
405
544
620
744
52.8
43.9
38.2
36.1
67.5
77.9
82.5
86.8
5,6 b-epoxy-
cholesterol
152
348
487
1491
38.4
35.6
36.6
32.2
5.1
17.6
65.6
164.5
7-ketocholesterol
187
343
603
1100
38.4
35.7
24.8
13.9
54.2
100.0
148.6
184.2
7b-hydroxy-
cholesterol
91
98
209
397
54.2
53.1
45.1
35.1
13.4
14.0
27.9
39.5
5,6 a-epoxy-
cholesterol
64.5
497
1512
3338
165.0
165.9
104.8
92.7
20.9
162.3
312.1
609.8
FIGURE 3 - Transfer of 14C-cholesterol oxide esters from HDL
3
 
and HDL
2
 to LDL, (A) in % of 14C-cholesterol transferred and 
(B) in nCi. Both with DTNB (LCAT inhibitor), with DTNB 
plus pCMPS (CETP inhibitor) , without DTNB and, without 
DTNB plus pCMPS. 
FIGURE 4 - Transfer of 14C-cholesterol oxide esters from HDL
3
 
and HDL
2
 to VLDL, (A) in % of 14C-cholesterol transferred and 
(B) in nCi. Both with DTNB, with DTNB plus pCMPS , without 
DTNB and without DTNB plus pCMPS.
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CONCLUSIONS
In conclusion, this study shows that cholesterol 
oxides are esterified by LCAT and that the efficiency of 
esterification differs among the different cholesterol oxi-
des present in HDL. Cholesterol oxides diminished the 
LCAT-catalyzed cholesterol esterification and this may 
have an important effect on reverse cholesterol transport. 
Thus, these data indicate that the effect of cholesterol oxi-
des on cholesterol esterification in HDL and on transfer of 
these cholesteryl esters to LDL and VLDL may contribute 
to the atherogenicity of these oxysterols.
AKNOWLEDGMENTS
This work was supported by Fundação de Ampa-
ro à Pesquisa do Estado de São Paulo (FAPESP, grant 
96/12164-0 to DSPA). Éder C. Pincinato was a fellowship 
holder of Fundação de Amparo à Pesquisa do Estado de 
São Paulo (FAPESP).
REFERENCES
ARON, L.; JONES, S.; FIELDING, C.J. Human plasma lecithin-
cholesterol acyltransferase. Characterization of cofactor-
dependent phospholipase activity. J. Biol. Chem. v.253, n.20, 
p.7220-7226, 1978.
BARTER, P.J.; RYE, K.A. Molecular mechanisms of reverse 
cholesterol transport. Curr. Opin. Lipidol., v.7, n.2, p.82-87, 
1996.
DOBIASOVA, M.; STRIBRNA, J.; PRITCHARD, P.H.; 
FROHLICH, J.J. Cholesterol esterification rate in plasma 
depleted of very low and low density lipoproteins is controlled 
by the proportion of HDL2 and HDL3 subclasses: study in 
hypertensive and normal middle-aged and septuagenarian men. 
J. Lipid Res., v.33, n.10, p.1411-1418, 1992.
DOBIASOVA, M.; STRIBRNA, J.; SPARKS, D.L.; PRITCHARD, 
P.H.; FROHLICH, J.J. Cholesterol esterification rates in very 
low density lipoprotein- and low density lipoprotein-depleted 
plasma. Relation to high density lipoprotein subspecies, sex, 
hyperlipidemia, and coronary artery disease. Arterioscler. 
Thromb., v.11, n.1, p.64-70, 1991.
ESTERBAUER, H., GEBICKI, J., PUHL, H., JURGENS, G. 
The role of lipid peroxidation and antioxidants in oxidative 
modification of LDL. Free Radical Biol. Med., v.13, n.4, 
p.341-390, 1992.
FERDERBAR, S.; PEREIRA, E.C.; APOLINÁRIO, E.; 
BERTOLAMI, M.C.; FALUDI, A.; MONTE, O.; CALLIARI, 
L.E.; SALES, J.E.; GAGLIARDI, A.R.; XAVIER, H.T.; 
ABDALLA, D.S. Cholesterol oxides as biomarkers of 
oxidative stress in type 1 and type 2 diabetes mellitus. Diabetes 
Metab. Res. Rev., v.23, n.1, p.35-42, 2007. 
FIELDING, C. J. Lecithin: cholesterol acyltransferase. In: 
ESFAHANI, M.; SWANEY, J. B. (Eds.). Advances in 
cholesterol research. New Jersey: Telford Press, 1990. p. 
271-314.
FIELDING, C.J.; FIELDING, P.E. Molecular physiology of 
reverse cholesterol transport. J. Lipid Res. v.36, n.2, p.211-228, 
1995. 
FIELDING, P. E.; ISHIKAWA, Y.; FIELDING, C. J. Apolipoprotein 
E mediates binding of normal very low density lipoprotein to 
heparin but is not required for high affinity receptor binding. 
J. Biol. Chem., v.264, n.21, p.12462-6, 1989.
FRUEBIS, J., PARTHASARATHY, S., STEINBERG, D. Evidence 
for a concerted reaction between lipid hydroperoxides and 
polypeptides. Proc. Natl. Acad. Sci. USA, v.89, n.22, p.10588-
10592, 1992.
GLOMSET, J.A. The plasma lecithins:cholesterol acyltransferase 
reaction. J. Lipid Res. v.9, n.2, p.155-167, 1968.
IGLESIAS, A.; ARRANZ, M.; ALVAREZ, J.J.; PERALES, J.; 
VILLAR, J.; HERRERA, E.; LASUNCIÓN, M.A. Cholesteryl 
ester transfer activity in liver disease and cholestasis, and its 
relation with fatty acid composition of lipoprotein lipids. Clin. 
Chim. Acta., v.248, n.2, p.157-174, 1996.
JONAS, A. Lecithin-cholesterol acyltransferase in the metabolism 
of high-density lipoproteins. Biochim. Biophys. Acta., v.1084, 
n.3, p.205-220, 1991.
KAWANO, M.; NAGASAKA, S.; YAGYU, H.; ISHIBASHI, S. 
Pitavastatin decreases plasma prebeta1-HDL concentration and 
might promote its disappearance rate in hypercholesterolemic 
patients. J. Atheroscler. Thromb., v.15, n.1, p. 41-46, 2008.
KILSDONK, E.P.; MOREL, D.W.; JOHNSON, W.J.; 
ROTHBLAT, G.H. Inhibition of cellular cholesterol efflux 
by 25-hydroxycholesterol. J. Lipid Res., v.36, n.3, p.505-516, 
1995.
Cholesterol oxides inhibit cholesterol esterification by lecithin:cholesterol 435
NISHIDA, H.I.; ARAI, H.; NISHIDA, T. Cholesterol ester transfer 
mediated by lipid transfer protein as influenced by changes 
in the charge characteristics of plasma lipoproteins. J. Biol. 
Chem., v.268, n.22, p.16352-16360, 1993.
ODA, H.; YAMASHITA, H.; KOSAHARA, K.; KUROKI, 
S.; NAKAYAMA, F. Esterified and total 7 alpha-
hydroxycholesterol in human serum as an indicator for hepatic 
bile acid synthesis. J. Lipid Res., v.31, n.12, p.2209-2218, 1990.
ORAM, J.F.; YOKOYAMA, S. Apolipoprotein-mediated removal 
of cellular cholesterol and phospholipids. J. Lipid Res. v.37, 
n.12, p.2473-2491, 1996.
PEELMAN, F.; VINAIMONT, N.; VERHEE, A.; VANLOO, 
B.; VERSCHELDE, J.L.; LABEUR, C.; SEGURET-
MACE, S.; DUVERGER, N.; HUTCHINSON, G.; 
VANDEKERCKHOVE, J.; TAVERNIER, J.; ROSSENEU, 
M. A proposed architecture for lecithin cholesterol acyl 
transferase (LCAT): identification of the catalytic triad and 
molecular modeling. Protein Sci., v.7, n.3, p.587-599, 1998.
PENG, S.K.; HU, B.; MORIN, R.J. Angiotoxicity and atherogenicity 
of cholesterol oxides. J. Clin. Lab. Anal., v.5, n.2, p.144-152, 
1991.;
REDGRAVE, T.G.; ROBERTS, D.C.; WEST, C.E. Separation of 
plasma lipoproteins by density-gradient ultracentrifugation. 
Anal. Biochem., v.65, n.1-2, p.42-49, 1975.
SCHROEPFER, G.J. JR. Oxysterols: modulators of cholesterol 
metabolism and other processes Physiol. Rev., v.80, n.1, p.361-
554, 2000.
SEVANIAN, A.; MCLEOD, L.L. Cholesterol autoxidation in 
phospholipid membrane bilayers. Lipids, v.22, n.9, p.627-636, 
1987.
SEVANIAN, A.; SERAGLIA, R.; TRALDI, P.; ROSSATO, 
P.; URSINI, F.; HODIS, H. Analysis of plasma cholesterol 
oxidation products using gas- and high-performance liquid 
chromatography/mass spectrometry. Free Radic. Biol. Med., 
v.17, n.5, p.397-409, 1994.
VAN REYK, D.M.; BROWN, A.J.; HULT’EN, L.M.; DEAN, 
R.T.; JESSUP, W. Oxysterols in biological systems: sources, 
metabolism and pathophysiological relevance. Redox Rep., 
v.11, n.6, p.255-262, 2006.
VON ECKARDSTEIN, A. Cholesterol efflux from macrophages 
and other cells. Curr. Opin. Lipidol. v.7, n.5, p.308-319, 1996.
Received for publication on 26th February 2008
Accepted for publication on 3rd June 2009
